http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389449-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51872a5a09cc9a30fcbd1153ee34cdc6 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
filingDate | 2018-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efebc780cb45ce40be7cc18db07451f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55cd957c484e153aee5fd14701f7bcb0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87d0cfa9ce06e5fe336abdabe98667b9 |
publicationDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-11389449-B2 |
titleOfInvention | Treatment of metabolic syndrome with an sGC stimulator |
abstract | The present invention provides a method of treating a subject with metabolic syndrome by administering a stimulator of soluble guanylate cyclase (sGC) (Compound I) either alone or in combination therapy with a blood glucose lowering (antihyperglycemic or antidiabetes) medication, a blood pressure lowering (anti-hypertensive) medication, an anti-hyperlipidemic medication, or combinations thereof. It also relates to a method of reducing the level of a clinical marker selected from the group comprising of fasting blood glucose levels, fasting blood insulin levels, hemoglobin A1C (HbA1C) levels, blood cholesterol levels (total or LDL), blood ApoB levels, HOMA-IR levels, blood triglyceride levels, blood concentration of ADMA, blood levels of alanine transaminase, aspartate transaminase, and GGT, body weight and abdominal circumference, or any combination of these markers thereof, in a subject in need thereof by administering a stimulator of sGC (Compound I) either alone or in combination therapy with a blood glucose lowering (antihyperglycemic or antidiabetes) medication, a blood pressure lowering (anti-hypertensive) medication, an anti-hyperlipidemic medication, or combinations thereof. |
priorityDate | 2017-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 749.